Search results
Results from the WOW.Com Content Network
Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.
The WHO Criteria, developed in the 1970s by the International Union Against Cancer and the World Health Organization, represented the first generally agreed specific criteria for the codification of tumor response evaluation. These criteria were first published in 1981. [2]
PET response criteria in solid tumors (PERCIST) is a set of rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, using positron emission tomography (PET). The criteria were published in May 2009 in the Journal of Nuclear Medicine (JNM). [1]
The response rate is the percentage of patients on whom a therapy has some defined effect; for example, the cancer shrinks or disappears after treatment. [ 9 ] When used as a clinical endpoint for trials of cancer treatments, this is often called the objective response rate (ORR).
Tumor response rate was the primary endpoint using Response Evaluation Criteria In Solid Tumors (RECIST) criteria, while time to progression (TTP), progression free survival (PFS) and overall survival (OS) were defined as the secondary endpoints. In this study, no significant difference between the groups was noted and both groups showed ...
Researchers have applied Hill’s criteria for causality in examining the evidence in several areas of epidemiology, including connections between exposures to molds and infant pulmonary hemorrhage, [14] ultraviolet B radiation, vitamin D and cancer, [15] [16] vitamin D and pregnancy and neonatal outcomes, [17] alcohol and cardiovascular ...
They explored the underlying immunology of the response and played a role in evaluating the first such drug in clinical trials for the treatment of advanced melanoma. [18] This led the development of new criteria for evaluating responses of cancer patients to immunotherapy in clinical trials. [19]
The Common Terminology Criteria for Adverse Events (CTCAE), [1] formerly called the Common Toxicity Criteria (CTC or NCI-CTC), are a set of criteria for the standardized classification of adverse events of drugs and treatment used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI).